Blood Glucose
Conditions
Brief summary
Randomized, balanced, incomplete block design exploratory study of efficacy, with 8 active treatments (4 treatments per subject; 35 or 37 subjects per treatment) compared to a reference treatment (all 72 subjects).
Detailed description
Incomplete block design cross over study in which the subjects consumed commercial rice porridge (60 grams of extruded rice to which 300 ml of boiling water was added) in the morning in a fasted state. On each visit one of the seven different natural exacts was mixed into this porridge just before consumption. The reference was consumed by all subjects and consisted of plain porridge with no extract added.
Interventions
OTHERMulberry fruit
OTHERMulberry leaf
OTHERWhite bean
OTHERApple
OTHERElderberry
OTHERTurmeric
OTHERRice porridge
Sponsors
Lambda Therapeutic Research Ltd.
Unilever R&D
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Randomization was generated by the bio-statistician CRO. Subjects and key study team personnel were blinded as much as possible with regard to the identification of specific treatments but their distinctive colors, flavors or tastes could not be masked. To ensure the study team was not apparently aware of the treatments being administered to subjects, persons who were involved in the preparation of test products were not involved in rest of the study. The sponsors team was blinded.
Intervention model description
Randomized, balanced, incomplete block design exploratory study of efficacy, with 8 active treatments (4 treatments per subject; 35 or 37 subjects per treatment) compared to a reference treatment (all 72 subjects).
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Is the volunteer willing to give his consent to participate in the study in writing? 2. Is the volunteer between the age of \>20 and \<50 yrs? 3. Is the volunteer's Body Mass Index (BMI) in between \>18 and \<25 kg/m2? 4. Lactase deficient as indicated by screening test1 5. Is the volunteer apparently healthy? \[No medical conditions which might affect study measurement, as judged by study physician or measured by questionnaire, and/or assessed by haematology, blood chemistry and urinalysis\] 6. Is the volunteer willing to comply to study protocol during the study? 7. Is the volunteer agreeing to be informed about medically relevant personal test-results by study physician? 8. Is the volunteer willing to refrain from drinking of alcohol on and one day before the blood withdrawal? 9. Is the fasting blood glucose value of the volunteer is \>3.4 and \<6.1 mmol/ litre (i.e. 62-110 mg/dl)? 10. Is the Haemoglobin level within normal reference range as judged by the research physician? 11. Is the volunteer literate?
Exclusion criteria
1. Is the volunteer an employee of Unilever, Hindustan Lever, or Lambda Therapeutics Research? 2. Has the volunteer participated in any other biomedical study 3 months before screening visit day of this study and/or participating in any other biomedical study during the study period? 3. Does the volunteer take too much of alcohol (\> 120 ml / week)? 4. Is the volunteer on a medically prescribed/slimming diet? 5. Does the volunteer work in night shifts (between 23.00 and 6.00 hrs) in the week preceding or during the study? 6. Is the volunteer using any medication including traditional medicines, vitamins, tonics which might interfere with study measurements, as judged by the PI and/or study physician? 7. Does the volunteer engage in intense exercise \> 10h/week? (Intense exercise is defined as exercise which induces sweating and causes sufficient breathlessness to limit conversation) 8. Has the volunteer reported weight loss/gain \> 10% of body weight in the 6 months preceding screening? 9. Has the volunteer donated any blood for 2 months prior to screening visit? 10. Does the volunteer urine analysis show any drug abuse? 11. Is the volunteer allergic to any food or cosmetics? 12. Does the volunteer smoke or consume tobacco in any form, and/or was smoking or consuming tobacco in any form for 6 months preceding the study and/or will be smoking or consuming tobacco in any form, during the study? 13. If female, is the volunteer pregnant or will she be planning pregnancy during the study period? 14. If female, is the volunteer lactating or has been lactating for 6 weeks before pre-study investigation and/or during the study period?
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-prandial blood glucose | Positive incremental Area under the glucose versus time Curve between 0 (before) and 2 hours. | Glucose concentration in venous plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Breath hydrogen excretion | Fifteen minutes before (basal) and 65, 125, 185, 245, 305, 365 and 425 minutes after the ingestion of the test products | Hydrogen gas in exhaled breath. When a subject produced 10 ppm hydrogen or more above the basal breath hydrogen level the treatment was regarded as a positive |
| Intestinal discomfort | Ten minutes before (baseline) and at 130, 250, 370 and 420 minutes after the ingestion of the test products. | An intestinal discomfort questionnaire was administered. The questionnaire asked whether subjects had experienced 1) flatulence, 2) nausea, 3) bloating or 4) pain in the bowels. Percentage of Yes scores was calculated per discomfort. |
| Stool consistency and number of stools | 24 hours before study product intake, during 7 hour the test day and in the 17 hours after the test day (telephone interview). | Stool consistency was evaluated by semi-quantitative Bristol scale (score between 1 = constipation and 7 = watery diarrhea). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Post-prandial serum insulin | Total Area under the insulin versus time Curve 0-2 hours after the intake. | Post-prandial serum insulin Area under versus time curves |
| Glucose in urine | Subjects were asked to empty their bladder before study product intake (-20 minutes) and again before leaving the site ( 450 minutes). In these two samples and in all additional urine samples voided while subjects were on site, glucose was analyzed | Glucose in urine was measured using dipsticks with a detection limit of 2.28 mmol/L |
Countries
India
Outcome results
None listed